“Teva Pharmaceutical Industries Ltd.’s (TEVA) sales and profit next year will miss analyst forecasts, the company said today as new Chief Executive Officer Jeremy Levin prepares to lay out his strategy for investors next month.
Revenue will be between $19.5 billion and $20.5 billion, and earnings excluding some costs will be between $4.85 and $5.15 a share, the Petach Tikva, Israel-based company said in a statement. Analysts predicted revenue of $20.8 billion and profit of $5.63 a share, based on theaverage estimates compiled by Bloomberg.”
If you enjoy the content at iBankCoin, please follow us on Twitter
